What We Do
Sanammad Pharmaceuticals, BV is an innovative pharmaceutical company focusing on research, development, and production of unique, designer drugs with high potency and efficiency and minimal potential side effects.
We partner with major pharmaceutical and chemical companies and produce designer drugs and pro-drugs as well as innovative consumer products. We provide innovative analgesic solutions with products containing both opioid as well as non-opioid compounds and cannabinoids. We are a contract manufacturer for unique proprietary products. We can white label our products for our customers depending on quantity of purchase and territory.
We possess proprietary technologies for procurement of highest purity cannabinoids and terpenes from natural/ botanical sources. We also utilize our proprietary technology for conversion of cannabinoids from lipid-soluble to water-soluble forms. One of the biggest challenges in the field of cannabinoids is the high volatility of THC in room air environment (oxidation and auto- catabolization). We have solved this problem via our proprietary technology for microencapsulation in super-critical oxygen-free, liquid nitrogen environment.
Research and development of analgesic pro-drugs utilizing ultra-low doses of opioid agonists and cannabinoids.
Development of a pharmaceutical compound containing opioid agonist/ antagonist and cannabinoid for the treatment of opioid addiction and cannabinoid dependence.
Working on synthetic cannabinoids for the treatment of nausea and vomiting utilizing our unique delivery system.
Developing for a third party, a drug utilizing the “entourage” effect of cannabinoids for the treatment of Tourette’s syndrome.
Preparing for clinical trials for the treatment of Irritable Bowel Syndrome utilizing our proprietary delivery platforms.
Waiting to receive approvals from Health Canada to commence a clinical trial in patients suffering from drug-related psychosis utilizing our proprietary technology.
Dr. George E. Anastassov
MD, DDS, MBA
Chief Executive Officer
Dr. Anastassov is the Chief Financial Officer and the Secretary of AXIM Biotechnologies, Inc. as of May 2014. Prior to that Dr. Anastassov was one of the founders and the CEO of CanChew Biotechnologies, LLC in 2012. Dr. Anastassov is also one of the founders and a Board Member and a general partner of Sanammad Foundation and Sanammad Pharmaceuticals; both companies originated and located in The Netherlands since 2009 and 2014, respectively. He is one of the developers of the first-in-the-world cannabinoid-containing chewing gum-based delivery system.
Dr. Anastassov possesses Medical and Dental Doctorates as well as an Executive MBA. Dr. Anastassov has been recognized in “Who’s Who in Medicine” as well as “Who’s Who in Business Professionals” numerous times. He is the recipient of multiple national and international professional and humanitarian awards. Dr. Anastassov has been actively involved in Research and Development in Medicine and Biotechnologies since 1987.
Dr. Philip A. Van Damme
DMD, MD, PhD
Chief Medical Officer
Dr. Philip. A. Van Damme is the Chief Scientific/Medical Officer of AXIM Biotechnologies Inc., as of May 2014. Prior to that, Dr. Van Damme was one of the founders and CSO of CanChew Biotechnologies LLC, in 2012. He is also one of the founders and President/Director of Sanammad Foundation and Sanammad Pharmaceuticals, both originated and located in The Netherlands since 2009 and 2014, respectively. He is one of the developers of the first-in-the-world cannabinoid-containing chewing gum-based delivery systems. Dr. Van Damme possesses Dental and Medical Doctorates as well as a Ph.D. in Medical Sciences and has been actively involved in Research and Development in Dentistry, Medicine, and Biotechnologies since 1983.
Chief Technology Officer
Lekhram Changoer is the Chief Technology Officer of AXIM Biotechnologies, Inc. as of May 2014. He holds a Bachelor’s Degree in Analytical/Organic Chemistry and a Master’s Degree in Organic Chemistry. He was one of the founders of CanChew Biotechnologies, LLC in 2012 and is a board member and partner of Sanammad Foundation and Sanammad Pharmaceuticals BV; both companies originated and located in The Netherlands since 2009 and 2014, respectively. He is the originator of multiple patents including patent-pending technology on chewing gum compositions comprising cannabinoids, together with his Sanammad partners. He has over 20 years of experience in the area of Sales & Marketing, R&D, product development, and quality assurance of technical, consumer healthcare and pharmaceutical products – all servicing European and other international markets. During his career, he has co-founded different intellectual property-based pharmaceutical and dental companies in different stages from clinical development to the global sales of registered products.